Adam's Take By Adam Feuerstein CytoDyn is in financial and clinical distress, newly filed annual report shows
Adam's Take By Adam Feuerstein CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure
Adam's Take By Adam Feuerstein FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility
Adam's Take By Adam Feuerstein A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it
Adam's Take By Adam Feuerstein CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study
Adam's Take By Adam Feuerstein Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic
Adam's Take By Adam Feuerstein Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response
Biotech By Adam Feuerstein CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions
Adam's Take By Adam Feuerstein Vertex, Amgen could be seeking new deals to fuel growth following pipeline stumbles
Adam's Take By Adam Feuerstein Failure has paid handsomely for Cassava Sciences’ CEO. His latest cash grab is a risky Alzheimer’s drug
Adam's Take By Adam Feuerstein Do surprise drug rejections signal a more conservative FDA? Don’t bet on it
Adam's Take By Adam Feuerstein Applied Therapeutics’ muted response to a clinical hold speaks volumes
Adam's Take By Adam Feuerstein ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress
Adam's Take By Adam Feuerstein Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock
Adam's Take By Adam Feuerstein With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith
Adam's Take By Adam Feuerstein CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed
Adam's Take By Adam Feuerstein Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock
Adam's Take By Adam Feuerstein Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last
Adam's Take By Adam Feuerstein Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence
Adam's Take By Adam Feuerstein Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals
Adam's Take By Adam Feuerstein Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too
Adam's Take By Adam Feuerstein Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers
Adam's Take By Adam Feuerstein Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst
Adam's Take By Adam Feuerstein TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin
Adam's Take By Adam Feuerstein Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug
Adam's Take By Adam Feuerstein ‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug
Adam's Take By Adam Feuerstein Investor impatience with Gilead reclamation project sparks acquisition chatter
Adam's Take By Adam Feuerstein If biotech had a Mount Rushmore, whose heads would you chisel in the granite?
Adam's Take By Adam Feuerstein As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking